MedTrace Logo

Integrating Clinical, Protein Expression, and Genetic Markers to Predict Lymphedema in Breast Cancer

NCT07252843 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2025-11-28

No results posted yet for this study

Summary

The goal of this observational ambidirectional cohort study is to develop a prediction model to identify the risk of lymphedema after axillary lymph node dissection (ALND) in patients with breast cancer. The main questions it aims to answer are:

* Can clinicopathological factors predict the development of lymphedema?
* Do protein expression profiles and genetic mutations increase susceptibility to lymphedema?

Participants will:

* Undergo clinical evaluation and indocyanine green (ICG) lymphography to diagnose lymphedema.
* Provide lymphatic tissue and blood samples during ALND surgery for immunohistochemical protein analysis and gene mutation assessment.
* Be followed over time to monitor the onset and progression of lymphedema.

Conditions

  • Lymphedema Arm

Sponsors & Collaborators

  • Fakultas Kedokteran Universitas Indonesia

    collaborator OTHER

  • Dharmais National Cancer Center Hospital

    lead OTHER_GOV

Principal Investigators

  • Rizky Ifandriani Putri, MD · Anatomical Pathology Department, Dharmais Cancer Hospital - National Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2024-03-21
Completion
2025-07-29

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07252843 on ClinicalTrials.gov